<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4278209</article-id><article-id pub-id-type="pmid">25501794</article-id><article-id pub-id-type="doi">10.3390/md12125916</article-id><article-id pub-id-type="publisher-id">marinedrugs-12-05916</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Marine <italic>Pseudovibrio</italic> sp. as a Novel Source of Antimicrobials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Crowley</surname><given-names>Susan P.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-12-05916">1</xref><xref ref-type="aff" rid="af2-marinedrugs-12-05916">2</xref></contrib><contrib contrib-type="author"><name><surname>O&#8217;Gara</surname><given-names>Fergal</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-12-05916">2</xref><xref ref-type="aff" rid="af3-marinedrugs-12-05916">3</xref></contrib><contrib contrib-type="author"><name><surname>O&#8217;Sullivan</surname><given-names>Orla</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-12-05916">1</xref><xref ref-type="aff" rid="af4-marinedrugs-12-05916">4</xref></contrib><contrib contrib-type="author"><name><surname>Cotter</surname><given-names>Paul D.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-12-05916">1</xref><xref ref-type="aff" rid="af4-marinedrugs-12-05916">4</xref><xref rid="c1-marinedrugs-12-05916" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Dobson</surname><given-names>Alan D. W.</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-12-05916">2</xref><xref ref-type="aff" rid="af5-marinedrugs-12-05916">5</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Taglialatela-Scafati</surname><given-names>Orazio</given-names></name><role>External Editor</role></contrib></contrib-group><aff id="af1-marinedrugs-12-05916"><label>1</label>Teagasc, Moorepark Food Research Centre, Fermoy Co. Cork, Ireland; E-Mails: <email>susan.crowley@teagasc.ie</email> (S.P.C.); <email>orla.osullivan@teagasc.ie</email> (O.O.S.)</aff><aff id="af2-marinedrugs-12-05916"><label>2</label>School of Microbiology, University College Cork, Western Road, Cork, Ireland; E-Mails: <email>f.ogara@ucc.ie</email> (F.O.G.); <email>a.dobson@ucc.ie</email> (A.D.W.D.)</aff><aff id="af3-marinedrugs-12-05916"><label>3</label>Biomerit Research Centre, University College Cork, Western Road, Cork, Ireland</aff><aff id="af4-marinedrugs-12-05916"><label>4</label>Alimentary Pharmabiotic Centre, Biosciences Institute, University College Cork, Western Road, Cork, Ireland</aff><aff id="af5-marinedrugs-12-05916"><label>5</label>Marine Biotechnology Centre, Environmental Research Institute, Lee Road, Cork, Ireland</aff><author-notes><corresp id="c1-marinedrugs-12-05916"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>paul.cotter@teagasc.ie</email>; Tel.: +353-025-42694; Fax: +353-025-42340.</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2014</year></pub-date><volume>12</volume><issue>12</issue><fpage>5916</fpage><lpage>5929</lpage><history><date date-type="received"><day>25</day><month>8</month><year>2014</year></date><date date-type="rev-recd"><day>24</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#169; 2014 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2014</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Antibiotic resistance among pathogenic microorganisms is becoming ever more common. Unfortunately, the development of new antibiotics which may combat resistance has decreased. Recently, however the oceans and the marine animals that reside there have received increased attention as a potential source for natural product discovery. Many marine eukaryotes interact and form close associations with microorganisms that inhabit their surfaces, many of which can inhibit the attachment, growth or survival of competitor species. It is the bioactive compounds responsible for the inhibition that is of interest to researchers on the hunt for novel bioactives. The genus <italic>Pseudovibrio</italic> has been repeatedly identified from the bacterial communities isolated from marine surfaces. In addition, antimicrobial activity assays have demonstrated significant antimicrobial producing capabilities throughout the genus. This review will describe the potency, spectrum and possible novelty of the compounds produced by these bacteria, while highlighting the capacity for this genus to produce natural antimicrobial compounds which could be employed to control undesirable bacteria in the healthcare and food production sectors.</p></abstract><kwd-group><kwd>antimicrobial</kwd><kwd>bioactives</kwd><kwd>marine</kwd><kwd>microorganism</kwd><kwd>resistance</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>Antibiotic resistance among pathogenic microorganisms is becoming ever more common. Recent data published by the Centre for Disease Control and Prevention (CDC), estimated that the number of illnesses and deaths caused by antibiotic resistance exceeded 2 million and 23,000, respectively, in the United States [<xref rid="B1-marinedrugs-12-05916" ref-type="bibr">1</xref>] and 25,000 deaths annually in Europe are attributed to resistant hospital infections [<xref rid="B2-marinedrugs-12-05916" ref-type="bibr">2</xref>]. Drug resistant pathogens are currently placing a heavy financial burden on health systems worldwide with infections due to selected multidrug-resistant bacteria in the EU estimated to result in extra health-care costs and productivity losses of at least &#8364;1.5 billion each year [<xref rid="B3-marinedrugs-12-05916" ref-type="bibr">3</xref>]. These worrying trends of increased multidrug resistance, has led to a call by The Infectious Disease Society of America, for the delivery of ten new antibiotic drugs by 2020 [<xref rid="B4-marinedrugs-12-05916" ref-type="bibr">4</xref>]. Unfortunately, however, the number of new antibiotics being developed has decreased, rather than increased, in recent years [<xref rid="B5-marinedrugs-12-05916" ref-type="bibr">5</xref>]. The ever reducing rate at which novel and potent antimicrobials are emerging [<xref rid="B6-marinedrugs-12-05916" ref-type="bibr">6</xref>] means we are becoming ever more dependent on our current arsenal of antibiotics, which are rapidly losing potency. There is an urgent need for the discovery and supply of novel and potent antimicrobials from natural resources. Nearly 10% of known biologically active natural products are of microbial origin [<xref rid="B6-marinedrugs-12-05916" ref-type="bibr">6</xref>], with terrestrial bacteria considered well studied when compared to marine bacteria, which have in recent years been increasingly recognised for their biotechnological potential [<xref rid="B7-marinedrugs-12-05916" ref-type="bibr">7</xref>]. Current estimates for the global market for Marine Biotechnology products and processes stand at &#8364;2.8 billion (2010) [<xref rid="B8-marinedrugs-12-05916" ref-type="bibr">8</xref>]. Not surprisingly, focus has recently shifted to the oceans as a potential source for natural product discovery. Antimicrobials derived from marine microorganisms are of particular interest due to the suite of compounds being produced [<xref rid="B9-marinedrugs-12-05916" ref-type="bibr">9</xref>,<xref rid="B10-marinedrugs-12-05916" ref-type="bibr">10</xref>,<xref rid="B11-marinedrugs-12-05916" ref-type="bibr">11</xref>,<xref rid="B12-marinedrugs-12-05916" ref-type="bibr">12</xref>,<xref rid="B13-marinedrugs-12-05916" ref-type="bibr">13</xref>,<xref rid="B14-marinedrugs-12-05916" ref-type="bibr">14</xref>]. The aim of this review is to highlight a marine-derived bacteria: <italic>Pseudovibrio</italic> spp., which have shown themselves to be producers of bioactives and propose that this genus is a novel and a relatively untapped source of antimicrobial compounds.</p></sec><sec><title>2. <italic>Pseudovibrio</italic> sp.</title><p>In recent years, interest in marine-derived <italic>Pseudovibrio</italic> has increased due to the dominance of the genus amongst host-associated microbial communities, the antimicrobial ability of the members and the potency, broad-spectrum and novelty of the compounds produced by these bacteria [<xref rid="B15-marinedrugs-12-05916" ref-type="bibr">15</xref>,<xref rid="B16-marinedrugs-12-05916" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-12-05916" ref-type="bibr">17</xref>,<xref rid="B18-marinedrugs-12-05916" ref-type="bibr">18</xref>,<xref rid="B19-marinedrugs-12-05916" ref-type="bibr">19</xref>]. Members of this genus are of the Rhodobacteracea family, Rhodobacterales order and alphaproteobacteria class. They have been obtained from numerous marine sources such as the surfaces of tunicates [<xref rid="B15-marinedrugs-12-05916" ref-type="bibr">15</xref>], sea squirts [<xref rid="B20-marinedrugs-12-05916" ref-type="bibr">20</xref>], coral [<xref rid="B21-marinedrugs-12-05916" ref-type="bibr">21</xref>], seawater [<xref rid="B22-marinedrugs-12-05916" ref-type="bibr">22</xref>], algae [<xref rid="B23-marinedrugs-12-05916" ref-type="bibr">23</xref>] and from a great variety of sponges worldwide, such as <italic>Axinella corrugata</italic>, <italic>Mycale laxissima</italic> from Florida [<xref rid="B24-marinedrugs-12-05916" ref-type="bibr">24</xref>]; <italic>E. discophorus</italic> from Portugal [<xref rid="B25-marinedrugs-12-05916" ref-type="bibr">25</xref>]; <italic>Irciniidae</italic> sponges also from Portuguese waters [<xref rid="B26-marinedrugs-12-05916" ref-type="bibr">26</xref>]; <italic>Didiscus oxeata</italic> from Jamaica [<xref rid="B27-marinedrugs-12-05916" ref-type="bibr">27</xref>]; <italic>P. magna</italic>, <italic>C. aurea</italic>, <italic>M. microsigmato</italic> from Brazil [<xref rid="B28-marinedrugs-12-05916" ref-type="bibr">28</xref>]; <italic>A. dissimilis</italic>, <italic>Polymastia boletiformis</italic> and <italic>H. simulans</italic> from Ireland [<xref rid="B12-marinedrugs-12-05916" ref-type="bibr">12</xref>], <italic>S. carnosus</italic>, <italic>Leucosolenia</italic> sp. from Lough Hyne, Ireland and <italic>Amphilectus fucorum</italic>, <italic>Eurypon major</italic> also from Irish coastal waters [<xref rid="B29-marinedrugs-12-05916" ref-type="bibr">29</xref>].</p><sec><title>2.1. Characterisation of the Genus Pseudovibrio</title><p>Even though the marine genus <italic>Pseudovibrio</italic> has been isolated throughout the marine environment, it was described for the first time only ten years ago. To date, four species have been described, <italic>i.e.</italic>, <italic>P. denitrificans</italic>, <italic>P. ascidiaceicola</italic>, <italic>P. japonicas</italic> and <italic>P. axinellae</italic> sp. nov. The first strain of the genus <italic>Pseudovibrio</italic> to be identified, a <italic>P. denitrificans</italic> isolate, was sourced from coastal seawater in 2004 [<xref rid="B22-marinedrugs-12-05916" ref-type="bibr">22</xref>]. More specifically, Shieh and colleagues isolated two denitrifying strains designated DN34T and DN33, from sea-water samples collected in Nanwan Bay, Kenting National Park, Taiwan which were named <italic>Pseudovibrio</italic> gen. nov. Characteristics associated with this species can be seen in <xref ref-type="table" rid="marinedrugs-12-05916-t001">Table 1</xref> [<xref rid="B22-marinedrugs-12-05916" ref-type="bibr">22</xref>]. In 2006, based on the results of phylogenetic and phenotypic analyses of two strains isolated from ascidians (sea squirts), a novel species, <italic>P. ascidiaceicola</italic> sp. nov. was proposed [<xref rid="B20-marinedrugs-12-05916" ref-type="bibr">20</xref>]. In addition to the results in <xref ref-type="table" rid="marinedrugs-12-05916-t001">Table 1</xref>, tests for &#946;-glucosidase, arginine dihydrolase and urease are positive. Indole is produced from tryptophan and gelatin and aesculin is hydrolysed [<xref rid="B20-marinedrugs-12-05916" ref-type="bibr">20</xref>]. <italic>Pseudovibrio japonicas</italic> strain WSF2T was isolated in 2007, from surface seawater off the coastline of the Boso Peninsula, Japan, and examined [<xref rid="B30-marinedrugs-12-05916" ref-type="bibr">30</xref>]. Tests in addition to those outlined in <xref ref-type="table" rid="marinedrugs-12-05916-t001">Table 1</xref> also yielded positive results for alkaline phosphatase, esterase (C4), esterase lipase (C8), leucine arylamidase, valine arylamidase, trypsin, acid phosphatase, naphthol-AS-BI-phosphohydrolase and &#946;-galactosidase [<xref rid="B30-marinedrugs-12-05916" ref-type="bibr">30</xref>]. More recently in 2013, O&#8217; Halloran <italic>et al.</italic> [<xref rid="B31-marinedrugs-12-05916" ref-type="bibr">31</xref>], described strain Ad2T which, on the basis of phylogenetic analysis, DNA-DNA hybridization and differential phenotypic characteristics, was proposed as the type strain of a novel species, for which the name <italic>Pseudovibrio axinellae</italic> sp. nov. was proposed. Tests in addition to those mentioned in <xref ref-type="table" rid="marinedrugs-12-05916-t001">Table 1</xref> revealed that aesculin, casein, DNA and gelatin are hydrolysed, while starch is not [<xref rid="B31-marinedrugs-12-05916" ref-type="bibr">31</xref>].</p><table-wrap id="marinedrugs-12-05916-t001" position="float"><object-id pub-id-type="pii">marinedrugs-12-05916-t001_Table 1</object-id><label>Table 1</label><caption><p>General characteristics of <italic>P. denitrificans</italic>, <italic>P. ascidiaceicola</italic>, <italic>P. japonicas</italic> and <italic>P. axinellae</italic> sp. nov.</p></caption></table-wrap></sec><sec><title>2.2. Bioactivity of the genus Pseudovibrio</title><p>The most commercially significant characteristic of <italic>Pseudovibrio</italic> strains is the production of secondary metabolites, which has been reported in many studies and will be discussed in detail below. Over the last decade there has been a considerable increase in the number of studies relating to the antimicrobial activity of a variety of bioactive compounds by <italic>Pseudovibrio</italic> spp. These studies highlight that this genus has the potential to be a particularly promising source of novel metabolites. Two families of enzymes, <italic>i.e</italic>., polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS), and their hybrids (PKS/NRPS) are of particular importance in the production of various secondary metabolites, many of which are important/natural products, across a wide range of microorganisms. Analysis of the presence of <italic>PKS</italic> and <italic>NRPS</italic> genes is often employed as a means of determining the likelihood that a microorganism has the potential to produce new bioactive compounds. For example, of the four <italic>Pseudovibrio</italic> cultures by Kennedy <italic>et al</italic>. [<xref rid="B32-marinedrugs-12-05916" ref-type="bibr">32</xref>] from the marine sponge <italic>H. simulans,</italic> two of which had 99% 16S rRNA gene identity match to <italic>P. ascidiaceicola</italic> F10102., three were found to contain both putative <italic>PKS</italic> and <italic>NRPS</italic> genes, suggesting a high potential for secondary metabolite production. In 2009, this group assessed the bioactivity of these <italic>Pseudovibrio</italic> bacteria [<xref rid="B19-marinedrugs-12-05916" ref-type="bibr">19</xref>]. The three <italic>Pseudovibrio</italic> strains, PV1, PV2, PV4, that contained <italic>PKS</italic> and <italic>NRPS</italic> genes exhibited antimicrobial activity against methicillin-resistant <italic>S. aureus</italic>, <italic>B. cereus</italic>, <italic>E. coli</italic> and <italic>B. subtilis</italic>. Interestingly, <italic>Pseudovibrio</italic> strain PV3 which did not contain <italic>PKS</italic> and <italic>NRPS</italic> genes, did not show antimicrobial activity against the target strains [<xref rid="B19-marinedrugs-12-05916" ref-type="bibr">19</xref>].</p><p>The presence of <italic>PKS</italic> and <italic>NRPS</italic> genes that might be involved in the production of secondary metabolites by sponge-associated microorganisms was also investigated in a study by Gra&#231;a <italic>et al.</italic> [<xref rid="B25-marinedrugs-12-05916" ref-type="bibr">25</xref>]. In agreement with previous studies [<xref rid="B33-marinedrugs-12-05916" ref-type="bibr">33</xref>], it was found that the majority of bioactive bacteria in which <italic>PKS-I</italic> and <italic>NRPS</italic> genes were detected were <italic>Pseudovibrio</italic>. More specifically, Gra&#231;a <italic>et al.</italic> found that of the 212 bacteria isolated from the marine sponge <italic>E. discophorus</italic>, 31% produced antimicrobial compounds. Of these 66 bioactive-producing isolates, the most bioactive genus was <italic>Pseudovibrio</italic> (47%) with bioactivity observed against <italic>B. subtilis</italic> ATCC6633, <italic>S. aureus</italic> MRSA and <italic>Aliivibrio fischeri</italic> CECT 524 [<xref rid="B25-marinedrugs-12-05916" ref-type="bibr">25</xref>]. This high level of activity within the genus has also been reported by Flemer <italic>et al.</italic> 2011 [<xref rid="B34-marinedrugs-12-05916" ref-type="bibr">34</xref>]. In that case out of the thirty <italic>Pseudovibrio</italic> strains isolated, 27 (90%) exhibited antimicrobial activity against at least two of three clinically relevant bacteria strains tested <italic>i.e.</italic>, <italic>E. coli</italic> NCIMB 12210, <italic>B. subtilis</italic> IA40, and <italic>S. aureus</italic> NCIMB 9518 [<xref rid="B34-marinedrugs-12-05916" ref-type="bibr">34</xref>]. The bioactivity profiles observed indicated the production of different antimicrobial compounds and again highlighted the broad range of activities associated with strains from this genus. This team also studied bioactive bacteria from the marine sponges <italic>A. fucorum</italic> and <italic>E. major</italic> [<xref rid="B29-marinedrugs-12-05916" ref-type="bibr">29</xref>]. In this instance, from the 409 bacterial strains isolated from both sponges and tested for antifungal and antibacterial activity, all of the strains exhibiting antibacterial activity were <italic>Pseudovibrio</italic> spp. More specifically, eight out of twelve <italic>Pseudovibrio</italic> strains isolated demonstrated activity. This activity was observed against at least one of the three targets employed, <italic>i.e</italic>., the aforementioned <italic>E. coli</italic> NCIMB 12210 as well as <italic>B. subtilis</italic> IE32 and <italic>S. aureus</italic> NC000949 [<xref rid="B29-marinedrugs-12-05916" ref-type="bibr">29</xref>].</p><p>Particularly broad spectrum activity by <italic>Pseudovibrio</italic> strains was demonstrated by Santos <italic>et al.</italic> [<xref rid="B28-marinedrugs-12-05916" ref-type="bibr">28</xref>]. <italic>Pseudovibrio</italic> strain Pm31 isolated from the sponge <italic>P. magna</italic>, strain Ca31 from <italic>C. aurea</italic> and strain Mm37 from <italic>Mycale microsimatosa</italic> demonstrated stable antimicrobial activity against Gram-positive targets <italic>Corynebacterium fimi</italic> NCTC 7547, <italic>Enterococcus faecium</italic> ATCC 19434, <italic>Enterococcus faecalis</italic> V583 (vancomycin), <italic>E. faecalis</italic> 5AE (vancomycin), <italic>S. aureus</italic> ATCC 29213, <italic>S. aureus</italic> 42AE (MRSA), <italic>S. aureus</italic> 559a (community-associated MRSA), <italic>Staphylococcus epidermidis</italic> ATCC 12228, <italic>S. epidermidis</italic> 57s (ampicillin, ciprofloxacin, penicillin, tetracycline), <italic>Staphylococcus haemolyticus</italic> ATCC 2997, <italic>S. haemolyticus</italic> 109s (ampicillin, gentamicin, oxacillin, penicillin), <italic>Staphylococcus hominis</italic> ATCC 27844, and against Gram-negative <italic>Acinetobacter calcoaceticus</italic> 56AE, <italic>E. coli</italic> 54 AE (ampicillin, chloramphenicol, trimethoprim/sulfamethoxazole, tetracyline), <italic>P. aeruginosa</italic> ATCC 27853, <italic>P. aeruginosa</italic> 3AE (aztreonam, piperacillin/tazobactam), and <italic>Salmonella enterica</italic> 4AE. It was noted that although activity was seen against both Gram-positive and Gram-negative target strains, the <italic>Pseudovibrio</italic> strains were more effective against Gram-positive bacteria. Tests to characterize the bioactive compound produced by the <italic>Pseudovibri</italic>o strains showed that the substances were resistant to the action of all proteolytic enzymes tested suggesting that these antimicrobial substances are not ribosomal proteins. Biofilm production by the isolated strains was observed and was particularly apparent when strains Pm31 and Mm37 were studied [<xref rid="B28-marinedrugs-12-05916" ref-type="bibr">28</xref>]. It has been hypothesized that the ability to produce antibacterial compounds combined with an enhancement in bio&#64257;lm formation may give bacteria a selective advantage and possible dominance over other surface-attached bacteria [<xref rid="B35-marinedrugs-12-05916" ref-type="bibr">35</xref>].</p><p>O&#8217;Halloran <italic>et al.</italic> [<xref rid="B33-marinedrugs-12-05916" ref-type="bibr">33</xref>], referred to briefly above, also demonstrated broad spectrum activity from among a population of 73 <italic>Pseudovibrio</italic> isolates from the marine sponges <italic>A. dissimilis</italic>, <italic>P. boletiformis</italic> and <italic>H. simulans.</italic> This involved an initial screen using deferred antagonism assays from which it was revealed that 62 isolates (84.9%) demonstrated antimicrobial activity against at least one of the indicator strains tested. The majority of the isolates showed activity against <italic>E. coli</italic> (58; 79.5%), <italic>S. Typhimurium</italic> (54; 74%), <italic>B. subtilis</italic> (49; 67.1%), <italic>S. aureus</italic> (54; 74.0%), MRSA (48; 65.8%), vancomycin intermediate <italic>S. aureus</italic> (VISA) (45; 61.6%), hVISA (47; 64.9%), <italic>C. perfringens</italic> (60; 82.2%) and <italic>C. difficile</italic> (55; 75.3%). Activity was also observed against <italic>Yersinia enterocolitica</italic> (1; 1.4%), <italic>B. cereus</italic> (4; 5.5%), <italic>E. faecium</italic> (6; 8.2%), vancomycin-resistant <italic>Enterococcus</italic> (VRE) (1; 1.4%) and <italic>L. monocytogenes</italic> (2; 2.7%). Fourteen different antimicrobial activity spectra were identified suggesting and that the <italic>Pseudovibrio</italic> spp. may be producing a number of different antimicrobial compounds. The <italic>Pseudovibrio</italic> isolates were also screened for the presence of <italic>PKS</italic> genes, using degenerate PCR, with keto synthase gene fragments being found in all 73 isolates.</p><p>Although secondary metabolite production and antimicrobial activity has been shown in many <italic>Pseudovibrio</italic>-related studies, in many cases the corresponding compounds have not been the focus of further analysis. However, some studies have characterised the relevant bioactive compounds. In one case, isolate Z143, a bacterium from a Philippine tunicate which had 100% 16S rRNA gene similarity with the <italic>P. denitrificans</italic> type strain DN34 was reported in 2007 by Sertan de-Guzman [<xref rid="B15-marinedrugs-12-05916" ref-type="bibr">15</xref>] as the first &#945;-proteobacterium to produce the red pigment heptylprodigiosin (<xref ref-type="fig" rid="marinedrugs-12-05916-f001">Figure 1</xref>A) also known as 16-methyl-15-heptyl-prodiginine, which shows anti-<italic>Staphylococcus aureus</italic> activity. Vizcaino <italic>et al.</italic> [<xref rid="B21-marinedrugs-12-05916" ref-type="bibr">21</xref>] revealed the production of a novel polypeptide, pseudovibrocin, which was isolated from three unique coral-derived bacteria with 99% 16S rRNA gene similarity to <italic>P. denitrificans</italic> that were capable of inhibiting Gram-positive and Gram-negative bacteria. An acetone extract of the associated cell-free supernatant was found to inhibit <italic>Kocuria</italic>
<italic>rhizophila</italic> and a methanol extract inhibited <italic>B. subtilis</italic>, <italic>Vibrio harveyi</italic> and <italic>V. coralliilyticus</italic>. High-performance liquid chromatography analysis of the methanol extract suggested the presence of at least two antibiotics, one of which shown to be pseudovibrocin. Geng and Belas [<xref rid="B16-marinedrugs-12-05916" ref-type="bibr">16</xref>] studied the biosynthesis of tropodithietic acid (TDA), a tropolone antibiotic, by a number of strains. In addition to other members of the Roseobacteracea family, <italic>i.e.</italic>, <italic>Silicibacter</italic> sp. TM1040 and <italic>Phaeobacter gallaeciensis</italic> (both genera known to be TDA producers), <italic>Pseudovibrio</italic> sp. JE062, previously isolated by Enticknap <italic>et al.</italic> [<xref rid="B24-marinedrugs-12-05916" ref-type="bibr">24</xref>] was also found to be a TDA producer. The twelve genes required for TDA biosynthesis in strain JE062 were identified by transposon insertion mutagenesis and the organization of a number of the associated genes, <italic>tdaA-F</italic>, was found to be identical to that of the other bacteria in this study. The production of TDA by another <italic>Pseudovibrio</italic> sp., strain D323 (<xref ref-type="fig" rid="marinedrugs-12-05916-f001">Figure 1</xref>B) has also been reported by Penesyan <italic>et al.</italic> [<xref rid="B23-marinedrugs-12-05916" ref-type="bibr">23</xref>]. This marine epiphytic strain was 99% 16S rRNA gene identical to <italic>P. ascidiaceicola</italic> (Genbank Acc. #AB175663) and exhibited antimicrobial activity against target strains from the phyla Alphaproteobacteria, Gammaproteobacteria, Bacteroidetes, Firmicutes and Actinobacteria. The authors in particular noted that TDA produced by D323 was highly active against <italic>Nautella</italic> sp. R11, which causes disease in a marine seaweed <italic>Delisea pulchra</italic>, thereby supporting the hypothesis that these host-associated bacteria serve as a defence against potential pathogenic surface colonisers.</p><p>Genome-based methods such as comparative bacterial genomics [<xref rid="B36-marinedrugs-12-05916" ref-type="bibr">36</xref>] and &#8220;genome scanning&#8221; of sequenced genomes of natural-product-producing bacteria [<xref rid="B37-marinedrugs-12-05916" ref-type="bibr">37</xref>] can also lead to valuable information on the diversity of bacterial species and can lead to bioactive product discovery. In this regard it is relevant that Bondarev <italic>et al.</italic> [<xref rid="B38-marinedrugs-12-05916" ref-type="bibr">38</xref>] carried out analysis of the genomes of two <italic>Pseudovibrio</italic> strains, JE062 and FO-BEG1, that originated from the coast of Florida. At the time of writing, strain FO-BEG1 is the only <italic>Pseudovibrio</italic> for which a fully sequenced closed genome sequence has been reported.</p><fig id="marinedrugs-12-05916-f001" position="float"><label>Figure 1</label><caption><p>Structures of <italic>Pseudovibrio</italic>-related antimicrobial compounds [<xref rid="B39-marinedrugs-12-05916" ref-type="bibr">39</xref>]: (<bold>A</bold>) Heptylprodigiosin; (<bold>B</bold>) Tropodithietic acid.</p></caption><graphic xlink:href="marinedrugs-12-05916-g001"/></fig><p>Genes involved in the biosynthesis of <italic>TDA</italic> were detected in FO-BEG1, and it was confirmed through culture-based methods that the strain is indeed a <italic>TDA</italic> producer. Although <italic>TDA</italic> production has been reported previously by other <italic>Pseudovibrio</italic> sp. [<xref rid="B23-marinedrugs-12-05916" ref-type="bibr">23</xref>,<xref rid="B40-marinedrugs-12-05916" ref-type="bibr">40</xref>], it is not clear how widely distributed this trait is. However, our own analysis of nine antimicrobial producing <italic>Pseudovibrio</italic> strains reveals the absence of <italic>TDA</italic> gene clusters from seven of these strains, indicating that this cluster may not be widely distributed [<xref rid="B41-marinedrugs-12-05916" ref-type="bibr">41</xref>]. Even in situations where the cluster is present, it is notable that culture conditions can impact on the production of <italic>TDA</italic> [<xref rid="B42-marinedrugs-12-05916" ref-type="bibr">42</xref>]. Indeed, <italic>TDA</italic> production has been detected during bacterial growth under static conditions [<xref rid="B38-marinedrugs-12-05916" ref-type="bibr">38</xref>], but not during incubation under agitation in broth, except for a brief period at approximately 10 hours after inoculation [<xref rid="B16-marinedrugs-12-05916" ref-type="bibr">16</xref>]. Another notable feature of the Bondarev study was the identification of genes predicted to encode a hybrid <italic>NRPS-PKS</italic> system in strain FO-BEG1, which resembled those previously associated with members of the Enterobacteriaceae [<xref rid="B43-marinedrugs-12-05916" ref-type="bibr">43</xref>]. More specifically, this cluster corresponds to a 50 kb genomic island which is architecturally similar to a <italic>NRPS-PKS</italic> system reported by Nougayr&#232;de <italic>et al.</italic> [<xref rid="B44-marinedrugs-12-05916" ref-type="bibr">44</xref>] and determined to be colibactin (an <italic>E. coli</italic> metabolite). Similarities in the architecture between these two <italic>NRPS-PKS</italic> systems led to the suggestion that the product of the <italic>Pseudovibrio</italic> FO-BEG1 cluster is colibactin. Again, it is not clear to what extent this cluster is distributed among <italic>Pseudovibrio</italic> sp. so we have employed a previously designed PCR primer set [<xref rid="B44-marinedrugs-12-05916" ref-type="bibr">44</xref>] to determine the distribution of the <italic>NRPS-PKS</italic> system within our nine <italic>Pseudovibrio</italic> strains, and detected the presence of these genes in all nine strains [<xref rid="B41-marinedrugs-12-05916" ref-type="bibr">41</xref>]. Romano <italic>et al</italic>. [<xref rid="B45-marinedrugs-12-05916" ref-type="bibr">45</xref>] also demonstrated the astonishing diversity of the exo-metabolome (extracellular metabolites) of strain FO-BEG1 and the drastic effect that phosphate limitation can have on its composition. More specifically, results showed that low phosphate concentrations can induce the production of secondary metabolites in <italic>Pseudovibrio</italic> FO-BEG1. Under phosphate limitation, a higher production of phenolic and polyphenolic compounds was also observed by Romano <italic>et al.</italic> [<xref rid="B45-marinedrugs-12-05916" ref-type="bibr">45</xref>] when cells entered stationary phase. It was suggested by the authors that some of these compounds may be tropone derivatives, of which TDA is an example, which are commonly produced by bacteria of the <italic>Roseobacter</italic> clade and can have antibacterial activity. Indeed members of the <italic>Roseobacter</italic> clade produce TDA in addition to an uncharacterised yellow pigment, which may be the same pigment produced in this study by <italic>Pseudovibrio</italic> under phosphate-limited conditions and entering stationary phase. In addition, several masses were predicted to correspond to cyclic dipeptides that resemble antimicrobials produced by <italic>Roseobacter</italic> strains isolated from marine sponges. Given the phylogenetic and physiological similarity between <italic>Roseobacter</italic> and <italic>Pseudovibrio</italic> bacteria, the authors reasoned that <italic>Pseudovibrio</italic> may also release such compounds into the medium [<xref rid="B45-marinedrugs-12-05916" ref-type="bibr">45</xref>].</p><p>Genomic analysis of <italic>Pseudovibrio</italic> FO-BEG1 (<xref ref-type="fig" rid="marinedrugs-12-05916-f002">Figure 2</xref>) and JE062 has also revealed the potential for a diverse array of metabolic abilities within both strains [<xref rid="B43-marinedrugs-12-05916" ref-type="bibr">43</xref>].</p><fig id="marinedrugs-12-05916-f002" position="float"><label>Figure 2</label><caption><p>Analysis of <italic>Pseudovibrio</italic> FO-BEG1 via antiSmash showing (<bold>A</bold>) Terpene type gene cluster; (<bold>B</bold>) Non-ribosomal peptide synthetases (NRPS)-polyketide synthases (PKS) cluster; (<bold>C</bold>) Putative bacteriocin 1; (<bold>D</bold>) Putative bacteriocin 2 ; and (<bold>E</bold>) T3pks-T1pks cluster on plasmid.</p></caption><graphic xlink:href="marinedrugs-12-05916-g002"/></fig><p>Analysis revealed the presence of genes predicted to be involved in carbohydrate, lipid, fatty acid, lipopolysaccharide, sugar and glycan metabolism. Pathways involved in terpenoid, sterol, cofactor and vitamin and polyamine biosynthesis have also been identified, as have genes predicted to be involved in the biosynthesis of secondary metabolites such as monolignol, flavanone, flavonoid and paspaline [<xref rid="B46-marinedrugs-12-05916" ref-type="bibr">46</xref>]. Our own unpublished analysis [<xref rid="B47-marinedrugs-12-05916" ref-type="bibr">47</xref>], of <italic>Pseudovibrio</italic> FO-BEG1 <italic>via</italic> antiSmash (antibiotics and Secondary Metabolite Analysis Shell) and BAGEL (prediction of bacteriocins in prokaryotes) have highlighted a number of clusters of interest. More specifically, antiSmash highlighted a terpene type gene cluster (<xref ref-type="fig" rid="marinedrugs-12-05916-f002">Figure 2</xref>A) and two putative bacteriocin clusters (<xref ref-type="fig" rid="marinedrugs-12-05916-f002">Figure 2</xref>C,D), in addition to the previously mentioned <italic>NRPS-PKS</italic> system (<xref ref-type="fig" rid="marinedrugs-12-05916-f002">Figure 2</xref>B) on the chromosome and a type T3pks-T1pks cluster on the plasmid (<xref ref-type="fig" rid="marinedrugs-12-05916-f002">Figure 2</xref>E) [<xref rid="B47-marinedrugs-12-05916" ref-type="bibr">47</xref>]. BAGEL also highlighted loci of significance related to putative bacteriocins [<xref rid="B48-marinedrugs-12-05916" ref-type="bibr">48</xref>].</p><p>Ultimately, although it is evident from the literature that <italic>Pseudovibrio</italic> sp. can possess broad range antimicrobial activity, in many cases the basis for this activity has not been further analysed. Therefore the opportunity to identify novel bioactive compounds exists. As previously mentioned, culture conditions can have a significant effect on the production of antimicrobials, which is often tightly regulated, and must be taken into consideration when designing experiments (<xref ref-type="fig" rid="marinedrugs-12-05916-f003">Figure 3</xref>) in order to establish the optimum conditions for maximum production of bioactives. The schematic diagram below outlines the procedures currently underway and being employed to study a number of <italic>Pseudovibrio</italic> strains and which may prove fruitful for others.</p><fig id="marinedrugs-12-05916-f003" position="float"><label>Figure 3</label><caption><p>Schematic diagram outlining relevant experimental procedures which may lead to the identification of novel bioactive molecules.</p></caption><graphic xlink:href="marinedrugs-12-05916-g003"/></fig><p>In addition to the identification of potentially novel bioactive compounds, the use of these approaches can allow one to demonstrate the spectrum of antimicrobial activity of the strains, facilitate the identification of putative bioactive clusters and to carry out comparative genomics.</p></sec></sec><sec><title>3. Conclusions</title><p>Antibiotic resistance among pathogenic microorganisms is becoming ever more common. Unfortunately, the development of new antibiotics which may combat these pathogens has decreased. Natural sources has provided, and can continue to provide, a diverse range of compounds for drug development and many of these biologically active natural products are of microbial origin. As the hunt for novel, natural and potent antibiotics continues, focus has recently shifted to the oceans for natural product discovery as the marine environment has revealed itself as the relatively untapped source of potent bioactives. In recent years, the marine-derived <italic>Pseudovibrio</italic> has been the focus of particular attention due to the dominance of the genus among host-associated microbial communities and its associated antimicrobial producing capabilities. More specifically, the potency, broad-spectrum and novelty of the compounds produced by these bacteria has highlighted this genus as a source of natural antimicrobial compounds which can potentially be employed to combat the prevalence of antibiotic resistant bacteria among the healthcare and food production sectors. Varying physiological growth conditions, gene expression and biological analysis, in addition to the knowledge gained through genome sequencing of members of the genus <italic>Pseudovibrio</italic>, may lead to the identification of genes involved in the production of secondary metabolites, optimum growth parameters and gene expression; eventually leading to the development of novel bioactives.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are funded by the Department of Agriculture, Food and the Marine Food Institutional Research Measure (FIRM) (MabS project No. 11/f/009), the Beaufort Marine Biodiscovery Research award funded by the Irish Government under the National Development Plan (2007&#8211;2013) and the PharmaSea project funded by the EU Seventh Framework Program.</p></ack><notes><title>Author Contributions</title><p>This review was conceived, designed and written by Susan P. Crowley, Alan D. W. Dobson and Paul D. Cotter. All authors discussed the content of the review. The review was polished by authors: Fergal O&#8217;Gara and Orla O&#8217;Sullivan.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-12-05916"><label>1.</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>United State Department of Health and Human Services</collab></person-group>
<source>Antibiotic Resistance Threats in the Unites States</source>
<publisher-name>Centers for Disease Control and Prevention</publisher-name>
<publisher-loc>Atlanta, GA, USA</publisher-loc>
<year>2013</year>
</element-citation></ref><ref id="B2-marinedrugs-12-05916"><label>2.</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>ECDC</collab></person-group>
<source>Annual Epidemiological Report 2012</source>
<publisher-name>European Center for Disease Prevention and Control</publisher-name>
<publisher-loc>Tomtebodav&#228;gen 11a, 17183, Stockholm, Sweden</publisher-loc>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ecdc.europa.eu/en/publications/Annual-Epidemiological-Report-2012.pdf">http://www.ecdc.europa.eu/en/publications/Annual-Epidemiological-Report-2012.pdf</ext-link></comment>
<date-in-citation>(accessed on 14 February 2014)</date-in-citation>
</element-citation></ref><ref id="B3-marinedrugs-12-05916"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanerva</surname><given-names>M.</given-names></name><name><surname>Ollgren</surname><given-names>J.</given-names></name><name><surname>Hakanen</surname><given-names>A.J.</given-names></name><name><surname>Lyytik&#228;inen</surname><given-names>O.</given-names></name></person-group>
<article-title>Estimating the burden of healthcare-associated infections caused by selected multidrug-resistant bacteria Finland, 2010</article-title>
<source>Antimicrob. Resist. Infect. Control</source>
<year>2012</year>
<volume>1</volume>
<pub-id pub-id-type="doi">10.1186/2047-2994-1-33</pub-id>
</element-citation></ref><ref id="B4-marinedrugs-12-05916"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><collab>Infectious Diseases Society of America</collab></person-group>
<article-title>The 10 &#215; '20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020</article-title>
<source>Clin. Infect. Dis.</source>
<year>2020</year>
<volume>50</volume>
<fpage>1081</fpage>
<lpage>1083</lpage>
</element-citation></ref><ref id="B5-marinedrugs-12-05916"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talbot</surname><given-names>G.H.</given-names></name><name><surname>Bradley</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>J.E.</given-names></name><name><surname>Gilbert</surname><given-names>D.</given-names></name><name><surname>Scheld</surname><given-names>M.</given-names></name><name><surname>Bartlett</surname><given-names>J.G.</given-names></name></person-group>
<article-title>Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America</article-title>
<source>Clin. Infect. Dis.</source>
<year>2006</year>
<volume>42</volume>
<fpage>657</fpage>
<lpage>668</lpage>
<pub-id pub-id-type="doi">10.1086/499819</pub-id>
<?supplied-pmid 16447111?><pub-id pub-id-type="pmid">16447111</pub-id></element-citation></ref><ref id="B6-marinedrugs-12-05916"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Penesyan</surname><given-names>A.</given-names></name><name><surname>Kjelleberg</surname><given-names>S.</given-names></name><name><surname>Egan</surname><given-names>S.</given-names></name></person-group>
<article-title>Development of novel drugs from marine surface associated microorganisms</article-title>
<source>Mar. Drugs</source>
<year>2010</year>
<volume>8</volume>
<fpage>438</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.3390/md8030438</pub-id>
<?supplied-pmid 20411108?><pub-id pub-id-type="pmid">20411108</pub-id></element-citation></ref><ref id="B7-marinedrugs-12-05916"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Penesyan</surname><given-names>A.</given-names></name><name><surname>Marshall-Jones</surname><given-names>Z.</given-names></name><name><surname>Holmstrom</surname><given-names>C.</given-names></name><name><surname>Kjelleberg</surname><given-names>S.</given-names></name><name><surname>Egan</surname><given-names>S.</given-names></name></person-group>
<article-title>Antimicrobial activity observed among cultured marine epiphytic bacteria refects their potential as a source of newdrugs</article-title>
<source>Fed. Eur. Microbiol. Soc.</source>
<year>2009</year>
<volume>69</volume>
<fpage>113</fpage>
<lpage>124</lpage>
</element-citation></ref><ref id="B8-marinedrugs-12-05916"><label>8.</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>European Science Foundation</collab></person-group>
<source>A New Vision and Strategy for Europe</source>
<publisher-name>Marine Board</publisher-name>
<publisher-loc>Ostend, Belgium</publisher-loc>
<year>2012</year>
</element-citation></ref><ref id="B9-marinedrugs-12-05916"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Discovery of novel metabolites from marine actinomycetes</article-title>
<source>Curr. Opin. Microbiol.</source>
<year>2006</year>
<volume>9</volume>
<fpage>245</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1016/j.mib.2006.03.004</pub-id>
<?supplied-pmid 16675289?><pub-id pub-id-type="pmid">16675289</pub-id></element-citation></ref><ref id="B10-marinedrugs-12-05916"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prudhomme</surname><given-names>J.</given-names></name><name><surname>McDaniel</surname><given-names>E.</given-names></name><name><surname>Ponts</surname><given-names>N.</given-names></name><name><surname>Bertani</surname><given-names>S.</given-names></name><name><surname>Fenical</surname><given-names>W.</given-names></name><name><surname>Jensen</surname><given-names>P.</given-names></name><name><surname>le Roch</surname><given-names>K.</given-names></name></person-group>
<article-title>Marine actinomycetes: A new source of compounds against the human malaria parasite</article-title>
<source>PLoS One</source>
<year>2008</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002335</pub-id>
</element-citation></ref><ref id="B11-marinedrugs-12-05916"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hentschel</surname><given-names>U.</given-names></name><name><surname>Schmid</surname><given-names>M.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Fieseler</surname><given-names>L.</given-names></name><name><surname>Gernert</surname><given-names>C.</given-names></name><name><surname>Hacker</surname><given-names>J.</given-names></name></person-group>
<article-title>Isolation and phylogenetic analysis of bacteria with antimicrobial activities from the Mediterranean sponges <italic>Aplysina aerophoba</italic> and <italic>Aplysina cavernicola</italic></article-title>
<source>FEMS Microbiol. Ecol.</source>
<year>2001</year>
<volume>35</volume>
<fpage>305</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6941.2001.tb00816.x</pub-id>
<?supplied-pmid 11311441?><pub-id pub-id-type="pmid">11311441</pub-id></element-citation></ref><ref id="B12-marinedrugs-12-05916"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viegelmann</surname><given-names>C.</given-names></name><name><surname>Margassery</surname><given-names>L.</given-names></name><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>OBrien</surname><given-names>C.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name><name><surname>Morrisssey</surname><given-names>J.</given-names></name><name><surname>Dobson</surname><given-names>A.</given-names></name><name><surname>Edrada-Ebel</surname><given-names>R.</given-names></name></person-group>
<article-title>Metabolomic profiling and genomic study of a marine sponge-associated <italic>Streptomyces</italic> sp.</article-title>
<source>Mar. Drugs</source>
<year>2014</year>
<volume>12</volume>
<fpage>3323</fpage>
<lpage>3351</lpage>
<pub-id pub-id-type="doi">10.3390/md12063323</pub-id>
<pub-id pub-id-type="pmid">24893324</pub-id></element-citation></ref><ref id="B13-marinedrugs-12-05916"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prieto</surname><given-names>M.L.</given-names></name><name><surname>O&#8217;Sullivan</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>S.P.</given-names></name><name><surname>McLoughlin</surname><given-names>P.</given-names></name><name><surname>Hughes</surname><given-names>H.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>P.M.</given-names></name><name><surname>Cotter</surname><given-names>P.D.</given-names></name><name><surname>Lawlor</surname><given-names>P.G.</given-names></name><name><surname>Gardiner</surname><given-names>G.E.</given-names></name></person-group>
<article-title>Assessment of the bacteriocinogenic potential of marine bacteria reveals lichenicidin production by seaweed-derived <italic>Bacillus</italic> spp.</article-title>
<source>Mar. Drugs</source>
<year>2012</year>
<volume>10</volume>
<fpage>2280</fpage>
<lpage>2299</lpage>
<pub-id pub-id-type="doi">10.3390/md10102280</pub-id>
<pub-id pub-id-type="pmid">23170084</pub-id></element-citation></ref><ref id="B14-marinedrugs-12-05916"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desriac</surname><given-names>F.</given-names></name><name><surname>J&#233;gou</surname><given-names>C.</given-names></name><name><surname>Balnois</surname><given-names>E.</given-names></name><name><surname>Brillet</surname><given-names>B.</given-names></name><name><surname>le Chevalier</surname><given-names>P.</given-names></name><name><surname>Fleury</surname><given-names>Y.</given-names></name></person-group>
<article-title>Antimicrobial peptides from marine proteobacteria</article-title>
<source>Mar. Drugs</source>
<year>2013</year>
<volume>11</volume>
<fpage>3632</fpage>
<lpage>3660</lpage>
<?supplied-pmid 24084784?><pub-id pub-id-type="pmid">24084784</pub-id></element-citation></ref><ref id="B15-marinedrugs-12-05916"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sertan-de Guzman</surname><given-names>A.A.</given-names></name><name><surname>Bernardo</surname><given-names>R.Z.</given-names></name><name><surname>Neilan</surname><given-names>B.A.</given-names></name><name><surname>Elardo</surname><given-names>S.P.</given-names></name><name><surname>Mangalindan</surname><given-names>G.C.</given-names></name><name><surname>Tasdemir</surname><given-names>D.</given-names></name><name><surname>Ireland</surname><given-names>C.M.</given-names></name><name><surname>Barraquio</surname><given-names>W.L.</given-names></name><name><surname>Concepcion</surname><given-names>G.P.</given-names></name></person-group>
<article-title><italic>Pseudovibrio denitrificans</italic> strain Z143-1, a heptylprodigiosin-producing bacterium isolated from a Philippine tunicate</article-title>
<source>FEMS Microbiol. Lett.</source>
<year>2007</year>
<volume>277</volume>
<fpage>188</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">18031339</pub-id></element-citation></ref><ref id="B16-marinedrugs-12-05916"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geng</surname><given-names>H.F.</given-names></name><name><surname>Belas</surname><given-names>R.</given-names></name></person-group>
<article-title>Expression of tropodithietic acid biosynthesis is controlled by a novel autoinducer</article-title>
<source>J. Bacteriol.</source>
<year>2010</year>
<volume>192</volume>
<fpage>4377</fpage>
<lpage>4387</lpage>
<pub-id pub-id-type="doi">10.1128/JB.00410-10</pub-id>
<?supplied-pmid 20601479?><pub-id pub-id-type="pmid">20601479</pub-id></element-citation></ref><ref id="B17-marinedrugs-12-05916"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Imhoff</surname><given-names>J.F.</given-names></name></person-group>
<article-title>Phylogenetic identification of bacteria with antimicrobial activities isolated from Mediterranean sponges</article-title>
<source>Biomol. Eng.</source>
<year>2003</year>
<volume>20</volume>
<fpage>421</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1016/S1389-0344(03)00069-8</pub-id>
<?supplied-pmid 12919828?><pub-id pub-id-type="pmid">12919828</pub-id></element-citation></ref><ref id="B18-marinedrugs-12-05916"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muscholl-Silberhorn</surname><given-names>A.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Imhoff</surname><given-names>J.F.</given-names></name></person-group>
<article-title>Abundance and bioactivity of cultured sponge-associated bacteria from the mediterranean sea</article-title>
<source>Microb. Ecol.</source>
<year>2008</year>
<volume>55</volume>
<fpage>94</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1007/s00248-007-9255-9</pub-id>
<?supplied-pmid 17497228?><pub-id pub-id-type="pmid">17497228</pub-id></element-citation></ref><ref id="B19-marinedrugs-12-05916"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>Baker</surname><given-names>P.</given-names></name><name><surname>Piper</surname><given-names>C.</given-names></name><name><surname>Cotter</surname><given-names>P.D.</given-names></name><name><surname>Walsh</surname><given-names>M.</given-names></name><name><surname>Mooij</surname><given-names>M.J.</given-names></name><name><surname>Bourke</surname><given-names>M.B.</given-names></name><name><surname>Rea</surname><given-names>M.C.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>P.M.</given-names></name><name><surname>Ross</surname><given-names>R.P.</given-names></name><etal/></person-group>
<article-title>Isolation and analysis of bacteria with antimicrobial activities from the marine sponge <italic>Haliclona simulans</italic> collected from Irish waters</article-title>
<source>Mar. Biotechnol.</source>
<year>2009</year>
<volume>11</volume>
<fpage>384</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="doi">10.1007/s10126-008-9154-1</pub-id>
<?supplied-pmid 18953608?><pub-id pub-id-type="pmid">18953608</pub-id></element-citation></ref><ref id="B20-marinedrugs-12-05916"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukunaga</surname><given-names>Y.</given-names></name><name><surname>Kurahashi</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Yanavfbgi</surname><given-names>K.</given-names></name><name><surname>Yokota</surname><given-names>A.</given-names></name><name><surname>Harayama</surname><given-names>S.</given-names></name></person-group>
<article-title><italic>Pseudovibrio ascidiaceicola</italic> sp. nov., isolated from ascidians (sea squirts)</article-title>
<source>Int. J. Syst. Evol. Microbiol.</source>
<year>2006</year>
<volume>56</volume>
<fpage>343</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1099/ijs.0.63879-0</pub-id>
<?supplied-pmid 16449437?><pub-id pub-id-type="pmid">16449437</pub-id></element-citation></ref><ref id="B21-marinedrugs-12-05916"><label>21.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>M.</given-names></name><name><surname>Moeller</surname><given-names>P.</given-names></name><name><surname>Morris</surname><given-names>P.</given-names></name></person-group>
<article-title>The Potential for the Marine Bacterium <italic>Pseudovibrio denitrificans</italic> to Produce Novel Antibiotics</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.musc.edu/mbes-ljg/MBESOpenHouse/2010/abstracts/Vizcaino-SROH_July_16_2010.pdf">https://www.musc.edu/mbes-ljg/MBESOpenHouse/2010/abstracts/Vizcaino-SROH_July_16_2010.pdf</ext-link></comment>
<date-in-citation>(accessed on 30 March 2014)</date-in-citation>
</element-citation></ref><ref id="B22-marinedrugs-12-05916"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shieh</surname><given-names>W.Y.</given-names></name><name><surname>Lin</surname><given-names>Y.T.</given-names></name><name><surname>Jean</surname><given-names>W.D.</given-names></name></person-group>
<article-title><italic>Pseudovibrio denitrificans</italic> gen. nov., sp. nov., a marine, facultatively anaerobic, fermentative bacterium capable of denitrification</article-title>
<source>Int. J. Syst. Evol. Microbiol.</source>
<year>2004</year>
<volume>54</volume>
<fpage>2307</fpage>
<lpage>2312</lpage>
<pub-id pub-id-type="doi">10.1099/ijs.0.63107-0</pub-id>
<?supplied-pmid 15545476?><pub-id pub-id-type="pmid">15545476</pub-id></element-citation></ref><ref id="B23-marinedrugs-12-05916"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Penesyan</surname><given-names>A.</given-names></name><name><surname>Tebben</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name><name><surname>Kjelleberg</surname><given-names>S.</given-names></name><name><surname>Harder</surname><given-names>T.</given-names></name><name><surname>Egan</surname><given-names>S.</given-names></name></person-group>
<article-title>Identification of the antibacterial compound produced by the marine epiphytic bacterium <italic>Pseudovibrio</italic> sp. D323 and related sponge-associated bacteria</article-title>
<source>Mar. Drugs</source>
<year>2011</year>
<volume>9</volume>
<fpage>1391</fpage>
<lpage>1402</lpage>
<pub-id pub-id-type="doi">10.3390/md9081391</pub-id>
<pub-id pub-id-type="pmid">21892353</pub-id></element-citation></ref><ref id="B24-marinedrugs-12-05916"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Enticknap</surname><given-names>J.J.</given-names></name><name><surname>Kelly</surname><given-names>M.</given-names></name><name><surname>Peraud</surname><given-names>O.</given-names></name><name><surname>Hill</surname><given-names>R.</given-names></name></person-group>
<article-title>Characterization of a culturable alphaproteobacterial symbiont common to many marine sponges and evidence for vertical transmission via sponge larvae</article-title>
<source>Appl. Environ. Microbiol.</source>
<year>2006</year>
<volume>72</volume>
<fpage>3724</fpage>
<lpage>3732</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.72.5.3724-3732.2006</pub-id>
<?supplied-pmid 16672523?><pub-id pub-id-type="pmid">16672523</pub-id></element-citation></ref><ref id="B25-marinedrugs-12-05916"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graca</surname><given-names>A.P.</given-names></name><name><surname>Bondoso</surname><given-names>J.</given-names></name><name><surname>Gaspar</surname><given-names>H.</given-names></name><name><surname>Xavier</surname><given-names>J.R.</given-names></name><name><surname>Monteiro</surname><given-names>M.C.</given-names></name><name><surname>de la Cruz</surname><given-names>M.</given-names></name><name><surname>Oves-Costales</surname><given-names>D.</given-names></name><name><surname>Vicente</surname><given-names>F.</given-names></name><name><surname>Lage</surname><given-names>O.M.</given-names></name></person-group>
<article-title>Antimicrobial Activity of Heterotrophic Bacterial Communities from the Marine Sponge <italic>Erylus discophorus</italic> (Astrophorida, Geodiidae)</article-title>
<source>PLoS One</source>
<year>2013</year>
<volume>8</volume>
<fpage>e78992</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0078992</pub-id>
<?supplied-pmid 24236081?><pub-id pub-id-type="pmid">24236081</pub-id></element-citation></ref><ref id="B26-marinedrugs-12-05916"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M.</given-names></name><name><surname>Radax</surname><given-names>R.</given-names></name><name><surname>Seger</surname><given-names>D.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name></person-group>
<article-title>Sponge-associated microorganisms: Evolution, ecology, and biotechnological potential</article-title>
<source>Microbiol. Mol. Biol. Rev.</source>
<year>2007</year>
<volume>71</volume>
<fpage>295</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1128/MMBR.00040-06</pub-id>
<?supplied-pmid 17554047?><pub-id pub-id-type="pmid">17554047</pub-id></element-citation></ref><ref id="B27-marinedrugs-12-05916"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteves</surname><given-names>A.I.</given-names></name><name><surname>Hardoim</surname><given-names>C.C.</given-names></name><name><surname>Xavier</surname><given-names>J.R.</given-names></name><name><surname>Goncalves</surname><given-names>J.M.</given-names></name><name><surname>Costa</surname><given-names>R.</given-names></name></person-group>
<article-title>Molecular richness and biotechnological potential of bacteria cultured from Irciniidae sponges in the north-east Atlantic</article-title>
<source>FEMS Microbiol. Ecol.</source>
<year>2013</year>
<volume>85</volume>
<fpage>519</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="doi">10.1111/1574-6941.12140</pub-id>
<pub-id pub-id-type="pmid">23621863</pub-id></element-citation></ref><ref id="B28-marinedrugs-12-05916"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santos</surname><given-names>O.C.</given-names></name><name><surname>Pontes</surname><given-names>P.V.</given-names></name><name><surname>Santos</surname><given-names>J.F.</given-names></name><name><surname>Muricy</surname><given-names>G.</given-names></name><name><surname>Giambiagi-deMarval</surname><given-names>M.</given-names></name><name><surname>Laport</surname><given-names>M.S.</given-names></name></person-group>
<article-title>Isolation, characterization and phylogeny of sponge-associated bacteria with antimicrobial activities from Brazil</article-title>
<source>Res. Microbiol.</source>
<year>2010</year>
<volume>161</volume>
<fpage>604</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1016/j.resmic.2010.05.013</pub-id>
<?supplied-pmid 20600863?><pub-id pub-id-type="pmid">20600863</pub-id></element-citation></ref><ref id="B29-marinedrugs-12-05916"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Margassery</surname><given-names>L.M.</given-names></name><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name><name><surname>Dobson</surname><given-names>A.D.</given-names></name><name><surname>Morrissey</surname><given-names>J.P.</given-names></name></person-group>
<article-title>Diversity and antibacterial activity of bacteria isolated from the coastal marine sponges <italic>Amphilectus fucorum</italic> and <italic>Eurypon major</italic></article-title>
<source>Lett. Appl. Microbiol.</source>
<year>2012</year>
<volume>55</volume>
<fpage>2</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1111/j.1472-765X.2012.03256.x</pub-id>
<?supplied-pmid 22519438?><pub-id pub-id-type="pmid">22519438</pub-id></element-citation></ref><ref id="B30-marinedrugs-12-05916"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hosoya</surname><given-names>S.</given-names></name><name><surname>Yokota</surname><given-names>A.</given-names></name></person-group>
<article-title><italic>Pseudovibrio japonicus</italic> sp. nov., isolated from coastal seawater in Japan</article-title>
<source>Int. J. Syst. Evol. Microbiol.</source>
<year>2007</year>
<volume>57</volume>
<fpage>1952</fpage>
<lpage>1955</lpage>
<pub-id pub-id-type="doi">10.1099/ijs.0.64922-0</pub-id>
<?supplied-pmid 17766853?><pub-id pub-id-type="pmid">17766853</pub-id></element-citation></ref><ref id="B31-marinedrugs-12-05916"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#8217;Halloran</surname><given-names>J.A.</given-names></name><name><surname>Barbosa</surname><given-names>T.M.</given-names></name><name><surname>Morrissey</surname><given-names>J.P.</given-names></name><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>Dobson</surname><given-names>A.D.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name></person-group>
<article-title><italic>Pseudovibrio axinellae</italic> sp. nov., isolated from an Irish marine sponge</article-title>
<source>Int. J. Syst. Evol. Microbiol.</source>
<year>2013</year>
<volume>63</volume>
<fpage>141</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1099/ijs.0.040196-0</pub-id>
<?supplied-pmid 22368168?><pub-id pub-id-type="pmid">22368168</pub-id></element-citation></ref><ref id="B32-marinedrugs-12-05916"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>Codling</surname><given-names>C.E.</given-names></name><name><surname>Jones</surname><given-names>B.V.</given-names></name><name><surname>Dobson</surname><given-names>A.D.</given-names></name><name><surname>Marchesi</surname><given-names>J.R.</given-names></name></person-group>
<article-title>Diversity of microbes associated with the marine sponge, <italic>Haliclona simulans</italic>, isolated from Irish waters and identification of polyketide synthase genes from the sponge metagenome</article-title>
<source>Environ. Microbiol.</source>
<year>2008</year>
<volume>10</volume>
<fpage>1888</fpage>
<lpage>1902</lpage>
<pub-id pub-id-type="doi">10.1111/j.1462-2920.2008.01614.x</pub-id>
<?supplied-pmid 18430018?><pub-id pub-id-type="pmid">18430018</pub-id></element-citation></ref><ref id="B33-marinedrugs-12-05916"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#8217;Halloran</surname><given-names>J.A.</given-names></name><name><surname>Barbosa</surname><given-names>T.M.</given-names></name><name><surname>Morrissey</surname><given-names>J.P.</given-names></name><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name><name><surname>Dobson</surname><given-names>A.D.</given-names></name></person-group>
<article-title>Diversity and antimicrobial activity of <italic>Pseudovibrio</italic> spp. from Irish marine sponges</article-title>
<source>J. Appl. Microbiol.</source>
<year>2011</year>
<volume>110</volume>
<fpage>1495</fpage>
<lpage>1508</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2672.2011.05008.x</pub-id>
<?supplied-pmid 21435124?><pub-id pub-id-type="pmid">21435124</pub-id></element-citation></ref><ref id="B34-marinedrugs-12-05916"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flemer</surname><given-names>B.</given-names></name><name><surname>Kennedy</surname><given-names>J.</given-names></name><name><surname>Margassery</surname><given-names>L.M.</given-names></name><name><surname>Morrissey</surname><given-names>J.P.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name><name><surname>Dobson</surname><given-names>A.D.</given-names></name></person-group>
<article-title>Diversity and antimicrobial activities of microbes from two Irish marine sponges, <italic>Suberites</italic>
<italic>carnosus</italic> and <italic>Leucosolenia</italic> sp.</article-title>
<source>J. Appl. Microbiol.</source>
<year>2011</year>
<volume>112</volume>
<fpage>289</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2672.2011.05211.x</pub-id>
<pub-id pub-id-type="pmid">22129274</pub-id></element-citation></ref><ref id="B35-marinedrugs-12-05916"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bruhn</surname><given-names>J.B.</given-names></name><name><surname>Gram</surname><given-names>L.</given-names></name><name><surname>Belas</surname><given-names>R.</given-names></name></person-group>
<article-title>Production of antibacterial compounds and biofilm formation by <italic>Roseobacter</italic> species are influenced by culture conditions</article-title>
<source>Appl. Environ. Microbiol.</source>
<year>2007</year>
<volume>73</volume>
<fpage>442</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.02238-06</pub-id>
<?supplied-pmid 17098910?><pub-id pub-id-type="pmid">17098910</pub-id></element-citation></ref><ref id="B36-marinedrugs-12-05916"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fern&#225;ndez-G&#243;mez</surname><given-names>B.</given-names></name><name><surname>Fern&#224;ndez-Guerra</surname><given-names>A.</given-names></name><name><surname>Casamayor</surname><given-names>E.O.</given-names></name><name><surname>Gonz&#225;lez</surname><given-names>J. M.</given-names></name><name><surname>Pedr&#243;s-Ali&#243;</surname><given-names>C.</given-names></name><name><surname>Acinas</surname><given-names>S.G.</given-names></name></person-group>
<article-title>Patterns and architecture of genomic islands in marine bacteria</article-title>
<source>BMC Genomics</source>
<year>2012</year>
<volume>13</volume>
<pub-id pub-id-type="doi">10.1186/1471-2164-13-347</pub-id>
<?supplied-pmid 23282288?><pub-id pub-id-type="pmid">23282288</pub-id></element-citation></ref><ref id="B37-marinedrugs-12-05916"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.Q.</given-names></name></person-group>
<article-title>Genome-based studies of marine of microorganisms to maximize the diversity of natural products discovery for medical treatments</article-title>
<source>Evid.-Based Complement. Altern. Med.</source>
<year>2011</year>
<volume>2011</volume>
<pub-id pub-id-type="doi">10.1155/2011/384572</pub-id>
</element-citation></ref><ref id="B38-marinedrugs-12-05916"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bondarev</surname><given-names>V.</given-names></name><name><surname>Rcchter</surname><given-names>M.</given-names></name><name><surname>Romano</surname><given-names>S.</given-names></name><name><surname>Piel</surname><given-names>J.</given-names></name><name><surname>Schwedt</surname><given-names>A.</given-names></name><name><surname>Schulz-Vogt</surname><given-names>H.N.</given-names></name></person-group>
<article-title>The genus <italic>Pseudovibrio</italic> contains metabolically versatile bacteria adapted for symbiosis</article-title>
<source>Environ. Microbiol.</source>
<year>2013</year>
<volume>15</volume>
<fpage>2095</fpage>
<lpage>2113</lpage>
<pub-id pub-id-type="doi">10.1111/1462-2920.12123</pub-id>
<pub-id pub-id-type="pmid">23601235</pub-id></element-citation></ref><ref id="B39-marinedrugs-12-05916"><label>39.</label><element-citation publication-type="webpage">
<article-title>CambridgeSoft Corporation, ChemBioDraw Software. 2012. PerkinElmer, 100 Cambridge Park Drive, Cambridge, MA 02140</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.cambridgesoft.com/Ensemble_for_Biology/ChemBioDraw/Default.aspx.">http://www.cambridgesoft.com/Ensemble_for_Biology/ChemBioDraw/Default.aspx.</ext-link></comment>
<date-in-citation>Analysis and visualisation of molecular structures (Accessed on 23 November 2014)</date-in-citation>
</element-citation></ref><ref id="B40-marinedrugs-12-05916"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>M.</given-names></name><name><surname>Neumann</surname><given-names>A.</given-names></name><name><surname>Schulz</surname><given-names>S.</given-names></name><name><surname>Simon</surname><given-names>M.</given-names></name><name><surname>Brinkhoff</surname><given-names>T.</given-names></name></person-group>
<article-title>Tropodithietic acid production in Phaeobacter gallaeciensis is regulated by <italic>N</italic>-acyl homoserine lactone-mediated quorum sensing</article-title>
<source>J. Bacteriol.</source>
<year>2011</year>
<volume>193</volume>
<fpage>6576</fpage>
<lpage>6585</lpage>
<pub-id pub-id-type="doi">10.1128/JB.05818-11</pub-id>
<?supplied-pmid 21949069?><pub-id pub-id-type="pmid">21949069</pub-id></element-citation></ref><ref id="B41-marinedrugs-12-05916"><label>41.</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Crowley</surname><given-names>S.P.</given-names></name><name><surname>O&#8217;Gara</surname><given-names>F.</given-names></name><name><surname>O&#8217;Sullivan</surname><given-names>O.</given-names></name><name><surname>Dobson</surname><given-names>A.D.W.</given-names></name><name><surname>Cotter</surname><given-names>P.C.</given-names></name></person-group>
<article-title><italic>Pseudovibrio</italic> isolates with anti-Salmonella activity</article-title>
<comment>In progress</comment>
</element-citation></ref><ref id="B42-marinedrugs-12-05916"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geng</surname><given-names>H.</given-names></name><name><surname>Bruhn</surname><given-names>J.B.</given-names></name><name><surname>Nielsen</surname><given-names>K.F.</given-names></name><name><surname>Gram</surname><given-names>L.</given-names></name><name><surname>Belas</surname><given-names>R.</given-names></name></person-group>
<article-title>Genetic dissection of tropodithietic acid biosynthesis by marine roseobacters</article-title>
<source>Appl. Environ. Microbiol.</source>
<year>2008</year>
<volume>74</volume>
<fpage>1535</fpage>
<lpage>1545</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.02339-07</pub-id>
<?supplied-pmid 18192410?><pub-id pub-id-type="pmid">18192410</pub-id></element-citation></ref><ref id="B43-marinedrugs-12-05916"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Putze</surname><given-names>J.</given-names></name><name><surname>Hennequin</surname><given-names>C.</given-names></name><name><surname>Nougayrede</surname><given-names>J.P.</given-names></name><name><surname>Zhang</surname><given-names>W.L.</given-names></name><name><surname>Homburg</surname><given-names>S.</given-names></name><name><surname>Karch</surname><given-names>H.</given-names></name><name><surname>Bringer</surname><given-names>M.A.</given-names></name><name><surname>Fayolle</surname><given-names>C.</given-names></name><name><surname>Carniel</surname><given-names>E.</given-names></name><name><surname>Rabsch</surname><given-names>W.</given-names></name><etal/></person-group>
<article-title>Genetic structure and distribution of the colibactin genomic island among members of the family enterobacteriaceae</article-title>
<source>Infect. Immun.</source>
<year>2009</year>
<volume>77</volume>
<fpage>4696</fpage>
<lpage>4703</lpage>
<pub-id pub-id-type="doi">10.1128/IAI.00522-09</pub-id>
<?supplied-pmid 19720753?><pub-id pub-id-type="pmid">19720753</pub-id></element-citation></ref><ref id="B44-marinedrugs-12-05916"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nougayr&#232;de</surname><given-names>J.P.</given-names></name><name><surname>Homburg</surname><given-names>S.</given-names></name><name><surname>Taieb</surname><given-names>F.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><name><surname>Brzuszkiewicz</surname><given-names>E.</given-names></name><name><surname>Gottschalk</surname><given-names>G.</given-names></name><name><surname>Buchrieser</surname><given-names>C.</given-names></name><name><surname>Hacker</surname><given-names>J.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group>
<article-title>Escherichia coli induces DNA double-strand breaks in eukaryotic cells</article-title>
<source>Science</source>
<year>2006</year>
<volume>313</volume>
<fpage>848</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="doi">10.1126/science.1127059</pub-id>
<?supplied-pmid 16902142?><pub-id pub-id-type="pmid">16902142</pub-id></element-citation></ref><ref id="B45-marinedrugs-12-05916"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romano</surname><given-names>S.</given-names></name><name><surname>Dittmar</surname><given-names>T.</given-names></name><name><surname>Bondarev</surname><given-names>V.</given-names></name><name><surname>Weber</surname><given-names>R.J.M.</given-names></name><name><surname>Viant</surname><given-names>M.R.</given-names></name><name><surname>Schulz-Vogt</surname><given-names>H.N.</given-names></name></person-group>
<article-title>Exo-Metabolome of <italic>Pseudovibrio</italic> sp. FO-BEG1 Analyzed by Ultra-High Resolution Mass Spectrometry and the Effect of Phosphate Limitation</article-title>
<source>PLoS One</source>
<year>2014</year>
<volume>9</volume>
<fpage>e96038</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0096038</pub-id>
<?supplied-pmid 24787987?><pub-id pub-id-type="pmid">24787987</pub-id></element-citation></ref><ref id="B46-marinedrugs-12-05916"><label>46.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Genomes</collab></person-group>
<article-title>Metabolic pathways&#8212;Pseudovibrio sp. FO-BEG1</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg-bin/show_pathway?psf01100">http://www.genome.jp/kegg-bin/show_pathway?psf01100</ext-link></comment>
<date-in-citation>(accessed on 20 August 2014)</date-in-citation>
</element-citation></ref><ref id="B47-marinedrugs-12-05916"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blin</surname><given-names>K.</given-names></name><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Kazempour</surname><given-names>D.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name><name><surname>Breitling</surname><given-names>R.</given-names></name><name><surname>Takano</surname><given-names>E.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group>
<article-title>AntiSMASH 2.0&#8212;A versatile platform for genome mining of secondary metabolite producers</article-title>
<source>Nucleic Acids Res.</source>
<year>2013</year>
<volume>41</volume>
<fpage>204</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt449</pub-id>
</element-citation></ref><ref id="B48-marinedrugs-12-05916"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Jong</surname><given-names>A.</given-names></name><name><surname>van Hijum</surname><given-names>S.A.F.T.</given-names></name><name><surname>Bijlsma</surname><given-names>J.J.E.</given-names></name><name><surname>Kok</surname><given-names>J.</given-names></name><name><surname>Kuipers</surname><given-names>O.P.</given-names></name></person-group>
<article-title>BAGEL: A web-based bacteriocin genome mining tool</article-title>
<source>Nucleic Acids Res.</source>
<year>2006</year>
<volume>34</volume>
<fpage>273</fpage>
<lpage>279</lpage>
</element-citation></ref></ref-list></back></article>